130 related articles for article (PubMed ID: 31629740)
1. Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells.
Abewe H; Deshmukh S; Mukim A; Beliakova-Bethell N
J Immunol Methods; 2020 Jan; 476():112674. PubMed ID: 31629740
[TBL] [Abstract][Full Text] [Related]
2. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Okamoto S; Echigoya Y; Tago A; Segawa T; Sato Y; Itou T
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834294
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Long Noncoding RNA Plasmacytoma Variant Translocation 1 with Antisense Locked Nucleic Acid GapmeRs Exerts Tumor-Suppressive Functions in Human Acute Erythroleukemia Cells Through Downregulation of
Salehi M; Sharifi M; Bagheri M
Cancer Biother Radiopharm; 2019 Aug; 34(6):371-379. PubMed ID: 30141968
[No Abstract] [Full Text] [Related]
5. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
[TBL] [Abstract][Full Text] [Related]
6. Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.
Kasuya T; Kugimiya A
Nucleic Acid Ther; 2018 Oct; 28(5):312-317. PubMed ID: 30095329
[TBL] [Abstract][Full Text] [Related]
7. Tips for Successful lncRNA Knockdown Using Gapmers.
Lennox KA; Behlke MA
Methods Mol Biol; 2020; 2176():121-140. PubMed ID: 32865787
[TBL] [Abstract][Full Text] [Related]
8. Invention and Early History of Gapmers.
Lim KRQ; Yokota T
Methods Mol Biol; 2020; 2176():3-19. PubMed ID: 32865779
[TBL] [Abstract][Full Text] [Related]
9. Non-Coding RNA Silencing in Mammalian Cells by Antisense LNA GapmeRs Transfection.
Alfeghaly C; Aigueperse C; Maenner S; Behm-Ansmant I
Methods Mol Biol; 2021; 2300():31-37. PubMed ID: 33792869
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of
Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
[TBL] [Abstract][Full Text] [Related]
11. Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity.
Cai Y; Makarova AM; Wengel J; Howard KA
J Gene Med; 2018 Jul; 20(7-8):e3025. PubMed ID: 29800498
[TBL] [Abstract][Full Text] [Related]
12. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
[TBL] [Abstract][Full Text] [Related]
13. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides.
Løvendorf MB; Holm A; Petri A; Thrue CA; Uchida S; Venø MT; Kauppinen S
Nucleic Acid Ther; 2023 Jan; 33(1):45-57. PubMed ID: 36445751
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
Iwashita S; Shoji T; Koizumi M
Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
[TBL] [Abstract][Full Text] [Related]
16. Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides.
Nguyen Q; Yokota T
Methods Mol Biol; 2020; 2176():99-109. PubMed ID: 32865785
[TBL] [Abstract][Full Text] [Related]
17. Antisense Gapmers with LNA-Wings and (
Zhou Y; Sakamoto S; Ueno Y
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364210
[TBL] [Abstract][Full Text] [Related]
18. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
19. Chemical modification study of antisense gapmers.
Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
[TBL] [Abstract][Full Text] [Related]
20. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides.
Hori S; Yamamoto T; Obika S
Biochem Biophys Res Commun; 2015 Aug; 464(2):506-11. PubMed ID: 26159921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
